Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
JCR Impact Factor: 0.1
ARTICLE
Year: 2019   |   Volume: 8   |   Issue: 4   |   Page: 139-143     View issue

Immunotherapy in breast cancer


Nematollah Rostami, Zeinab Mazloumi, Fatemeh Aghamaleki, Sima Rad, Abolfazl Movafagh, Mojgan Sheikhpour
Abstract

Over the last few years, the developments around cancer immunotherapy have led to a paradigm shift in the treatment of many different cancers and leukemias, in particular, melanoma, renal, bladder, and lung cancers with a remarkable impact on response rate and most importantly, overall survival was noticed. Breast cancer is most commonly considered to be a “noninflamed” cancer, and hence, this shift has been less marked within its treatment. However, some subsets of breast cancer, most notably triple-negative breast cancer, are deemed to be more “inflamed” and therefore may prove to be an appropriate cohort for immunotherapy.

Cite this article
Vancouver
Rostami N, Mazloumi Z, Aghamaleki F, Rad S, Movafagh A, Sheikhpour M. Immunotherapy in breast cancer. Clin Cancer Investig J. 2019;8(4):139-43. https://doi.org/10.4103/ccij.ccij_45_19
APA
Rostami, N., Mazloumi, Z., Aghamaleki, F., Rad, S., Movafagh, A., & Sheikhpour, M. (2019). Immunotherapy in breast cancer. Clinical Cancer Investigation Journal, 8(4), 139-143. https://doi.org/10.4103/ccij.ccij_45_19

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513